Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
Helen M. Parrington, Nurgun Kose, Erica Armstrong, Laura Handal, Summer Diaz, Joseph Reidy, Jinhui Dong, Guillaume B.E. Stewart-Jones, Punya Shrivastava-Ranjan, Shilpi Jain, César G. Albariño, Robert H. Carnahan, James E. Crowe Jr.
Helen M. Parrington, Nurgun Kose, Erica Armstrong, Laura Handal, Summer Diaz, Joseph Reidy, Jinhui Dong, Guillaume B.E. Stewart-Jones, Punya Shrivastava-Ranjan, Shilpi Jain, César G. Albariño, Robert H. Carnahan, James E. Crowe Jr.
View: Text | PDF
Research Article Immunology Infectious disease

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus

  • Text
  • PDF
Abstract

Sosuga virus (SOSV) is a recently discovered paramyxovirus with a single known human case of disease. There has been little laboratory research on SOSV pathogenesis or immunity, and no approved therapeutics or vaccines are available. Here, we report the discovery of human mAbs from the circulating memory B cells of the only known human case and survivor of SOSV infection. We isolated 6 mAbs recognizing the functional attachment protein hemagglutinin-neuraminidase (HN) and 18 mAbs against the fusion (F) protein. The anti-HN mAbs all targeted the globular head of the HN protein and could be organized into 4 competition-binding groups that exhibited epitope diversity. The anti-F mAbs can be divided into pre- or postfusion conformation-specific categories and further into 8 competition-binding groups. The only Ab in the panel that did not display neutralization activity was the single postfusion-specific anti-F mAb. Most of the anti-HN mAbs were more potently neutralizing than the anti-F mAbs, with mAbs in 1 of the HN competition-binding groups possessing ultrapotent (<1 ng/mL) half-maximal inhibitory virus neutralization values. These findings provide insight into the molecular basis for human Ab recognition of paramyxovirus surface proteins and the mechanisms of SOSV neutralization.

Authors

Helen M. Parrington, Nurgun Kose, Erica Armstrong, Laura Handal, Summer Diaz, Joseph Reidy, Jinhui Dong, Guillaume B.E. Stewart-Jones, Punya Shrivastava-Ranjan, Shilpi Jain, César G. Albariño, Robert H. Carnahan, James E. Crowe Jr.

×

Figure 2

SOSV HN and F soluble protein designs.

Options: View larger image (or click on image) Download as PowerPoint
SOSV HN and F soluble protein designs.
Soluble versions of the SOSV HN a...
Soluble versions of the SOSV HN and F proteins were generated by removing the cytoplasmic tail and transmembrane domains and adding a human CD5 or mouse IL-2 signal peptide. To aid in purification, a 6-His tag or StrepII tags were added to the carboxy (F) or amino (HN) terminal ends. (A) HNecto design includes a longer portion of the stalk region starting at residue 75, while the HNhead construct is composed of nearly only the globular head domain of the HN protein. (B) Additional modifications were necessary to include in the SOSV F prefusion (preF-tHS) construct, which included removal of the furin cleavage site and creation of a stabilizing disulfide bond by point mutations to cysteines at 206 and 223. The postfusion construct of SOSV F (postF-tHS) more closely resembles the WT sequence but with replacement of the cytoplasmic and transmembrane domains with a GCNt trimerization domain (also in preF-tHS).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts